CY1115018T1 - Αναστολεις cxcr1/2 ως ανοσοενισχυτικα στη μεταμοσχευση παγκρεατικων νησιδων - Google Patents

Αναστολεις cxcr1/2 ως ανοσοενισχυτικα στη μεταμοσχευση παγκρεατικων νησιδων

Info

Publication number
CY1115018T1
CY1115018T1 CY20141100185T CY141100185T CY1115018T1 CY 1115018 T1 CY1115018 T1 CY 1115018T1 CY 20141100185 T CY20141100185 T CY 20141100185T CY 141100185 T CY141100185 T CY 141100185T CY 1115018 T1 CY1115018 T1 CY 1115018T1
Authority
CY
Cyprus
Prior art keywords
cxcr1
pancreatic islet
immunosuppressants
suspensions
islet transplantation
Prior art date
Application number
CY20141100185T
Other languages
Greek (el)
English (en)
Inventor
Lorenzo Piemonti
Luisa Daffonchio
Marcello Allegretti
Original Assignee
Dompé S.p.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompé S.p.A. filed Critical Dompé S.p.A.
Publication of CY1115018T1 publication Critical patent/CY1115018T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51Y being a hydrogen or a carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY20141100185T 2009-10-06 2014-03-07 Αναστολεις cxcr1/2 ως ανοσοενισχυτικα στη μεταμοσχευση παγκρεατικων νησιδων CY1115018T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09172364A EP2308484A1 (en) 2009-10-06 2009-10-06 Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
EP10761018.0A EP2485723B1 (en) 2009-10-06 2010-10-06 Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets

Publications (1)

Publication Number Publication Date
CY1115018T1 true CY1115018T1 (el) 2017-01-25

Family

ID=41818891

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100185T CY1115018T1 (el) 2009-10-06 2014-03-07 Αναστολεις cxcr1/2 ως ανοσοενισχυτικα στη μεταμοσχευση παγκρεατικων νησιδων

Country Status (24)

Country Link
US (1) US20120202884A1 (enExample)
EP (2) EP2308484A1 (enExample)
JP (2) JP5834010B2 (enExample)
KR (2) KR101817912B1 (enExample)
CN (2) CN104906572A (enExample)
AU (1) AU2010305385B2 (enExample)
BR (1) BR112012007991B8 (enExample)
CA (1) CA2775902C (enExample)
CY (1) CY1115018T1 (enExample)
DK (1) DK2485723T3 (enExample)
EA (1) EA021298B1 (enExample)
ES (1) ES2451349T3 (enExample)
HK (1) HK1213777A1 (enExample)
HR (1) HRP20140202T1 (enExample)
IL (1) IL219037A (enExample)
ME (1) ME01719B (enExample)
MX (1) MX2012004082A (enExample)
NZ (1) NZ599172A (enExample)
PL (1) PL2485723T3 (enExample)
PT (1) PT2485723E (enExample)
RS (1) RS53249B (enExample)
SI (1) SI2485723T1 (enExample)
SM (1) SMT201400033B (enExample)
WO (1) WO2011042466A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
CN103159652B (zh) * 2011-12-19 2016-06-08 天津市国际生物医药联合研究院 亚磺酰胺类化合物的制备及其应用
CN105722972A (zh) 2013-06-18 2016-06-29 纽约大学 参与金黄色葡萄球菌杀白细胞素的细胞毒性的细胞因素:新型治疗靶点
CN109890364B (zh) 2016-10-03 2023-10-17 儿童医疗中心公司 糖尿病肾病的预防和治疗

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303249B1 (it) 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
US20020042370A1 (en) * 2000-04-14 2002-04-11 Millennium Pharmaceuticals, Inc. Method of treating graft rejection using inhibitors of CCR2 function
WO2001078708A1 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Treating graft rejection with cxcr3 inhibitors
ITMI20010206A1 (it) 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
PT1776336E (pt) * 2004-03-23 2009-12-18 Dompe Spa Derivados de ácido 2-fenilpropiónico e composições farmacêuticas que os contêm
EP1579859B1 (en) 2004-03-25 2006-12-13 DOMPE' pha.r.ma s.p.a. Use of N-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury
US20050261762A1 (en) * 2004-05-21 2005-11-24 Medtronic Vascular, Inc. Medical devices to prevent or inhibit restenosis
TWI400232B (zh) * 2004-09-13 2013-07-01 Ono Pharmaceutical Co 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑
JP5232144B2 (ja) * 2006-06-28 2013-07-10 サノフイ Cxcr2阻害剤
JP2010504996A (ja) * 2006-09-26 2010-02-18 ケース ウエスタン リザーブ ユニバーシティ サイトカインシグナリング
WO2009117706A2 (en) 2008-03-20 2009-09-24 Carolus Therapeutics, Inc. Methods of treatment using anti-mif antibodies
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets

Also Published As

Publication number Publication date
EP2485723B1 (en) 2013-12-11
SMT201400033B (it) 2014-07-07
BR112012007991A2 (pt) 2017-07-25
EA201270513A1 (ru) 2012-11-30
MX2012004082A (es) 2012-07-25
EA021298B1 (ru) 2015-05-29
DK2485723T3 (en) 2014-03-17
US20120202884A1 (en) 2012-08-09
RS53249B (sr) 2014-08-29
KR101817912B1 (ko) 2018-02-21
KR101759362B1 (ko) 2017-07-18
JP2015145404A (ja) 2015-08-13
JP2013506704A (ja) 2013-02-28
SI2485723T1 (sl) 2014-06-30
EP2308484A1 (en) 2011-04-13
EP2485723A1 (en) 2012-08-15
ME01719B (me) 2014-09-20
CN102665703A (zh) 2012-09-12
CN102665703B (zh) 2016-04-20
AU2010305385B2 (en) 2016-04-21
JP6097328B2 (ja) 2017-03-15
HRP20140202T1 (en) 2014-05-23
HK1213777A1 (zh) 2016-07-15
BR112012007991B8 (pt) 2021-05-25
AU2010305385A1 (en) 2012-04-26
NZ599172A (en) 2014-03-28
BR112012007991B1 (pt) 2020-12-15
PT2485723E (pt) 2014-03-13
CN104906572A (zh) 2015-09-16
CA2775902A1 (en) 2011-04-14
IL219037A (en) 2015-01-29
IL219037A0 (en) 2012-06-28
JP5834010B2 (ja) 2015-12-16
CA2775902C (en) 2016-11-29
ES2451349T3 (es) 2014-03-26
KR20120083440A (ko) 2012-07-25
HK1175993A1 (zh) 2013-07-19
KR20170068625A (ko) 2017-06-19
PL2485723T3 (pl) 2014-07-31
WO2011042466A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
CY1126771T1 (el) Συνδυασμοι δολουτεγραβιρης και λαμιβουδινης για την αγωγη λοιμωξης απο hiv
CY1117776T1 (el) Εναντιομερη ενωσεων σπειρο-οξινδολιου και οι χρησεις τους ως θεραπευτικοι παραγοντες
CY1123213T1 (el) Αλκυλαμιδο ενωσεις και οι χρησεις τους
CY1123308T1 (el) Αναστολεας ινωσης
CY1116945T1 (el) Παραγωγα ινδολιζινης, διεργασια για την παρασκευη αυτης και θεραπευτικη χρηση αυτης
CY1119669T1 (el) Παραγωγα 1-φαινυλ-2-πυριδινυλ-αλκυλ-αλκοολων ως αναστολεις φωσφοδιεστερασης
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
CY1119077T1 (el) Παραγωγα πυραζολυλαμινοπυριδινης χρησιμα ως αναστολεις κινασων
CY1118143T1 (el) Ετεροκυκλικες ενωσεις χρησιμες ως αναστολεις της pdk1
CY1113924T1 (el) Ενωσεις καρβαζολης και θεραπευτικες χρησεις των ενωσεων
EA201000050A1 (ru) Замещенные бициклолактамные соединения
CY1114764T1 (el) Παραγωγα προλινης ως αναστολεις καθεψινης
CY1110900T1 (el) Χημικες ενωσεις
EA201200631A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
DK1853588T3 (da) Kemiske forbindelser
UY32146A (es) Derivados de las 5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-nicotinamidas n-(sustituidas) y de las n-{5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-piridin-3-il}-benzamidas sustituidas y composiciones conteniéndolos
CY1115919T1 (el) Ενωσεις ενεργοποιησης τελομερασης και μεθοδοι χρησης αυτων
CY1108183T1 (el) Θειαζολυλο-διυδρο-ινδαζολια
CY1118390T1 (el) Θεραπευτικος παραγων για τη φλεγμονωδη νοσο του εντερου
CY1114865T1 (el) Νεοι αναστολεις seh και η χρηση toyς
CY1115018T1 (el) Αναστολεις cxcr1/2 ως ανοσοενισχυτικα στη μεταμοσχευση παγκρεατικων νησιδων
NI201100093A (es) 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5-hidroxitriptamina-6.
CY1115800T1 (el) Παραγωγα της 3-(ετεροαρυλο-αμινο)-1,2,3,4-τετραϋδρo-9η-καρβαζολης και η χρηση τους ως ρυθμιστες των υποδοχεων της προσταγλανδινης d2
CY1119040T1 (el) Μεθοδος για την παρασκευη 1-([1,3]διοξολαν-4-υλομεθυλο)-1η-πυραζολ-3-υλαμινης
NO20080265L (no) 2-(1H-indolylsulfanyl)-arylaminderivater